Exploring immunotherapy efficacy in non-small cell lung cancer patients with BRAF mutations: a case series and literature review
Immunotherapy can benefit NSCLC patients with BRAF mutations, though its efficacy is affected by comorbidities and brain metastases. The use of NGS enhances mutation detection, highlighting the need for personalized treatment approaches in NSCLC management. The varying responses to treatments among the patients emphasize the complexity of NSCLC management and the necessity for a personalized approach.
Authors
- Anna Grenda (ORCID: https://orcid.org/0000-0002-2112-8092)
- Paweł Krawczyk (ORCID: https://orcid.org/0000-0001-6907-6423)
- Michał Gil (ORCID: https://orcid.org/0000-0002-9965-261X)
- Izabela Chmielewska (ORCID: https://orcid.org/0000-0002-0948-9071)
- Robert Kieszko (ORCID: https://orcid.org/0000-0001-5775-0193)
- Janusz Milanowski (ORCID: https://orcid.org/0000-0002-8616-596X)
- Katarzyna Stencel (ORCID: https://orcid.org/0000-0003-0857-2030)
- Magdalena Wójcik-Superczyńska (ORCID: https://orcid.org/0000-0002-1544-3029)
- Tomasz Jankowski (ORCID: https://orcid.org/0000-0002-0049-7673)
Institutions
- Medical University of Lublin (PL)
- Greater Poland Cancer Center (PL)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2024-10-01
- DOI
- https://doi.org/10.21037/tlcr-24-253
- Citations
- 2
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.47